Roche will present new data from across its Alzheimer’s disease portfolio at the Alzheimer’s Association International Conference (AAIC) 2026 in London, highlighting its integrated approach to advancing both diagnostics and therapeutics. The company will share findings from 18 oral and poster presentations focused on earlier detection, intervention and disease prevention, with the goal of slowing or preventing the progression of Alzheimer’s disease.
A key focus will be trontinemab, Roche’s investigational Brainshuttle™ therapy designed to target amyloid-beta in the brain. New long-term data from the Phase Ib/IIa Brainshuttle AD study will be presented, alongside details of the Phase III PrevenTRON trial, which aims to evaluate trontinemab in cognitively unimpaired individuals at high risk of developing symptomatic Alzheimer’s disease. Roche will also share research on neuroinflammatory pathways, including the NLRP3 inflammasome, as a potential target for future Alzheimer’s and neurodegenerative disease treatments.
On the diagnostics side, Roche will present new evidence supporting its Elecsys pTau217 and pTau181 blood tests, which are designed to improve access to Alzheimer’s diagnosis in both primary and secondary care settings. The company says these blood-based biomarkers have the potential to help reduce diagnostic barriers, support earlier identification of at-risk individuals and improve access to appropriate care and treatment.
Read more about Roche’s latest Alzheimer’s disease research and innovations on the company website.
